DDInter1268 DDInter1938
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Vincristine is a vinca alkaloid with formula C46H56N4O10 found in the Madagascar periwinkle, Catharanthus roseus. It is used (commonly as the corresponding sulfate salt)as a chemotherapy drug for the treatment of leukaemia, lymphoma, myeloma, breast cancer and head and neck cancer. It has a role as a tubulin modulator, a microtubule-destabilising agent, a plant metabolite, an antineoplastic agent and a drug. It is a methyl ester, an acetate ester, a tertiary alcohol, a member of formamides, an organic heteropentacyclic compound, an organic heterotetracyclic compound, a tertiary amino compound and a vinca alkaloid. It is a conjugate base of a vincristine(2+). It derives from a hydride of a vincaleukoblastine.
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Voacamine
Voacamine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) NQO1
NQO1 {u} (Gene) is downregulated by {v} (Compound) Vincristine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Vinblastine
Vinblastine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Vinorelbine
Vinorelbine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Clostridium tetani toxoid antigen (formaldehyde inactivated) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinorelbine
Vinorelbine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Voacamine
Voacamine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clostridium tetani toxoid antigen (formaldehyde inactivated)
Clostridium tetani toxoid antigen (formaldehyde inactivated) {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vinblastine
Vinblastine {u} (Compound) resembles {v} (Compound) Vincristine
Natalizumab may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine (Compound) resembles Voacamine (Compound) and Voacamine (Compound) resembles Vincristine (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds NQO1 (Gene) and NQO1 (Gene) is downregulated by Vincristine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine (Compound) resembles Vincristine (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine (Compound) resembles Voacamine (Compound) and Voacamine (Compound) resembles Vincristine (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine (Compound) resembles Vincristine (Compound)